Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday

Adverum Biotechnologies (NASDAQ:ADVM) is expected to be issuing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($1.80) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 7, 2025 at 9:30 AM ET.

Adverum Biotechnologies (NASDAQ:ADVM) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($2.34) earnings per share for the quarter, missing the consensus estimate of ($2.24) by ($0.10). On average, analysts expect Adverum Biotechnologies to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Adverum Biotechnologies Trading Up 1.7%

Shares of ADVM stock opened at $4.30 on Friday. The firm has a market capitalization of $90.21 million, a P/E ratio of -0.55 and a beta of 0.98. Adverum Biotechnologies has a 1 year low of $1.78 and a 1 year high of $8.18. The firm’s fifty day simple moving average is $3.98 and its 200 day simple moving average is $3.08.

Hedge Funds Weigh In On Adverum Biotechnologies

A number of institutional investors and hedge funds have recently bought and sold shares of ADVM. XTX Topco Ltd bought a new stake in shares of Adverum Biotechnologies during the second quarter worth $64,000. Qube Research & Technologies Ltd acquired a new position in Adverum Biotechnologies during the 2nd quarter worth about $66,000. Marshall Wace LLP bought a new stake in Adverum Biotechnologies during the 2nd quarter worth about $107,000. AQR Capital Management LLC acquired a new stake in Adverum Biotechnologies in the 1st quarter valued at about $148,000. Finally, Jane Street Group LLC bought a new position in shares of Adverum Biotechnologies in the second quarter worth about $153,000. Institutional investors and hedge funds own 48.17% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on ADVM shares. Chardan Capital downgraded shares of Adverum Biotechnologies from a “strong-buy” rating to a “hold” rating in a report on Monday, October 27th. Truist Financial set a $5.00 price target on Adverum Biotechnologies in a research note on Friday, October 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adverum Biotechnologies in a report on Wednesday, October 8th. Mizuho set a $5.50 price objective on Adverum Biotechnologies in a report on Wednesday. Finally, Royal Bank Of Canada set a $4.00 target price on Adverum Biotechnologies in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $15.50.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.